截至5月6日收盘，衍生集团（06893.HK）报0.180港元，较上个交易日上涨0.56%，当日盘中最低价触 及0.165港元，创近一年新低。 衍生集团(国际)控股有限公司(股份代号:6893)专注于开发儿科保健品、中成药、及中医相关的健康项 目。集团于1996年成立,业务遍及中国内地、香港、澳门、台湾及东南亚等地区,积极达致品牌及产品多 元化发展,照顾各个家庭的健康需要。集团以专业的管理、进取的精神、严谨的态度,凭借雄厚的实力,已 成为集研发设计、生产加工、策划推广、市场营销、物流配送为一体的中医儿童专业服务与管理企业, 并积极发展中医药文化教育及生态产业。集团旗下生产基地'衍生健康医药产业园'位于广东省云浮市云 城区,已通过'食品生产许可SC认证',具备多条可作全自动生产包装的流水线,以生产衍生品牌系列食品、 保健品等产品为主,同时专业提供优质的符合GMP要求的外品牌委托加工生产(OEM)及受委托研发设计 生产代工策划(ODM)服务,业务涵盖饮料、方便食品、糖果制品等健康食品类目。'衍生'品牌严选本草精 华,配合现代高科技,推出多元化的保健药品及食品,当中多款产品已获发中成药注册(HKC)编号,通过多项 ...

Revenue and Sales Performance - Total revenue for the six months ended September 30, 2024, was HKD 52,318,000, representing an increase from HKD 46,214,000 for the same period in 2023, reflecting a growth of approximately 13.5%[1] - Sales of health products amounted to HKD 50,618,000, while personal care products generated HKD 1,140,000, indicating a significant contribution to overall revenue[1] - The group's revenue from the Hong Kong market for the six months ended September 30, 2024, was approximately HKD 29.4 million, a decrease from HKD 39 million in 2023, representing 63.7% of total revenue compared to 74.6% in 2023[45] - Revenue from the mainland China market increased to approximately HKD 16.8 million for the same period, up from HKD 13.3 million in 2023, accounting for 36.3% of total revenue compared to 25.4% in 2023[45] - The group's revenue for the period was approximately HKD 46.2 million, a decrease of about 11.7% compared to HKD 52.3 million in the same period of 2023[57] - The product development segment accounted for approximately 98.0% of total revenue, slightly down from 98.1% in 2023[57] - The health segment contributed approximately 0.7% to total revenue, up from about 0.6% in 2023[57] - Revenue from the product development division decreased by approximately HKD 6.1 million, a decline of about 11.8% compared to the same period in 2023, primarily due to reduced income from the Hong Kong market[85] - Revenue from the e-commerce platform accounted for approximately HKD 8.2 million, a slight increase from HKD 8.1 million in 2023, reflecting the growing trend of online shopping, especially in mainland China[84] Financial Performance and Losses - The company reported a net loss of HKD 18,873,000 for the six months ended September 30, 2024, compared to a loss of HKD 10,450,000 for the same period in 2023, representing an increase in losses of approximately 80.5%[8] - The group recorded a net loss of approximately HKD 19.2 million for the period, compared to a net loss of approximately HKD 10.5 million in the same period of 2023[72] - The net loss for the period was HKD 19,242,000, which is an increase from a net loss of HKD 10,462,000 in the same period last year, representing an increase of about 84.5%[183] - The basic and diluted loss per share for the period was HKD 1.73, compared to HKD 0.96 in the same period last year, indicating a deterioration in earnings per share[183] Assets and Liabilities - The company’s total assets and liabilities will be further detailed in the upcoming financial reports, indicating ongoing assessments for future growth strategies[11] - As of September 30, 2024, the total assets amounted to HKD 599,560,000, an increase from HKD 587,854,000 as of March 31, 2024, representing a growth of approximately 1.2%[176] - The total liabilities as of September 30, 2024, were HKD 400,727,000, slightly up from HKD 374,576,000 as of March 31, 2024, indicating an increase of about 7%[178] - Current liabilities exceeded current assets by approximately HKD 196,704,000, indicating significant uncertainty regarding the group's ability to continue as a going concern[192] Operational Strategies and Future Plans - The group plans to phase out low-margin products and allocate more resources to the product development segment, which is expected to yield higher profit margins[48] - The group plans to expand its e-commerce presence and has implemented marketing strategies to enhance brand influence and customer loyalty[67] - The group plans to expand its distribution network in mainland China, particularly in the children's health supplement market, which is expected to benefit from the implementation of China's "three-child" policy[82] - The group is implementing strategies to improve profitability and operational performance, including enhancing production efficiency of proprietary brand products[192] - The group aims to reduce product costs through in-house production as part of its business strategy[192] Shareholder Information and Corporate Governance - 彭少衍为主要股东，持有554,242,000股股份，约占50.76%[127] - 截至2024年9月30日，已发行股份总数为1,091,796,000股[126] - The audit committee consists of three independent non-executive directors, ensuring compliance with corporate governance codes[137] - The company has established a risk management and internal control system overseen by the audit committee[137] - The board consists of seven directors, including two executive directors and three independent non-executive directors[162] Cash Flow and Financial Management - The company’s cash and cash equivalents at the end of the period were HKD 5,231,000, compared to HKD 3,621,000 at the end of the same period last year, showing an increase of approximately 44.5%[187] - The operating cash flow for the period was a net outflow of HKD 11,175,000, compared to a net inflow of HKD 5,616,000 in the same period last year[187] - The group maintains ongoing communication with its main banks, with no indication of banks intending to withdraw financing or demand early repayment[192] - The board believes that the group will have sufficient working capital to meet its operational and financial obligations for the next twelve months due to expected bank loan renewals and available bank financing[196] Tax and Other Income - The company’s tax expense for the period included HKD 229,000 for Hong Kong profits tax, compared to HKD 8,000 in the previous year, indicating a significant increase in tax obligations[5] - Other income decreased by approximately 12.4% to about HKD 0.7 million for the six months ended September 30, 2024, primarily due to a decline in fair value gains on financial assets measured at fair value through profit or loss, which fell by about 9.2% to approximately HKD 1.8 million[27] - Other income increased by approximately 79.1% to about HKD 1.8 million, driven by government subsidies and the confirmation of customer deposit forfeitures[88] Legal and Compliance Matters - The group confirmed a provision of approximately HKD 18 million in the profit and loss account related to legal costs and unpaid construction costs[123] - The company has established a crisis management team to handle emergencies related to product safety[172] - The company ensures compliance with applicable laws and regulations through its risk management and internal control systems[159]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：6893） 截至2024年9月30日止六個月之 中期業績公佈 | --- | --- | --- | --- | |---------------------------------|-------------------|---------------|--------| | | | | | | 財務摘要 | 截至 9月30 六個月 | 日止 | | | | 2024 | 2023 | 變動 | | | 千港元 | 千港元 | % | | 收入 | 46,214 52,318 | | (11.7) | | 毛利 | 30,012 32,597 | | (7.9) | | 本期間虧損 | (19,242) (10,462) | | 83.9 | | 其他全面收益（開支）期間 | | 8,744 (8,606) | | | 每股虧損 – 基本及攤薄（港仙） | ...

已出席會議╱有權出席會議之次數 董事會會議 董事會與管理層 59 衍生集團（國際）控股有限公司 二零二三/二零二四年年度報告 董事會授權 除定期董事會會議外，管理層亦每週舉行會議以審閲、討論財務及營運事宜並就此作出決定。 企業管治報告 企業管治報告 彭少衍先生（主席）為關麗雯女士之配偶。除以上披露者外，董事之間概無其他關係（包括財務、商業、 親屬或其他重大╱相關的關係）。 執行董事向高級管理人員授權部分日常管理、行政和營運。在上述人員進行重大交易之前，必須經董事會 批准。董事會還得到執行董事及高級管理層的全面支持以履行職責。 就本企業管治報告而言，管理層包括執行董事、高級管理人員及部門主管。彼等於執行董事的領導下，負 責本集團的日常營運、管理及行政。彼等亦會執行及落實董事會釐定的策略和指示。 衍生集團（國際）控股有限公司 二零二三/二零二四年年度報告 60 根據企業管治守則的守則條文第 C.2.1 條，主席與行政總裁的角色應有區分，並不應由一人同時兼任。彭少 衍先生為本公司的主席兼行政總裁。鑒於彭先生為本集團共同創辦人之一及自 1996 年以來一直有效地經營 與管理本集團，故董事會認為以彭先生在行業中淵博的知 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼羣島註冊成立之有限公司） （股份代號：6893） 截至2024年3月31日止年度之 年度業績公告 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至3月31日止年度 | | | | | 2024 | 2023 | 變動 | | | 千港元 | 千港元 | % | | 收入 | 92,617 | 81,460 | 13.7 | | 毛利 | 57,406 | 38,836 | 47.8 | | 年內虧損 | (36,400) | (49,168) | (26.0) | | 年內其他全面收入╱（開支） | 5,820 | (12,721) | 145.8 | | 每股虧損 | | | | | – 基本及攤薄 （港仙） | (3.36) | (4.53) | | – 1 – 業績 董事會宣佈衍生集團（國際）控股有限公司及其附屬公司截至2024年3月31日止年 ...

| 目錄 1 | | --- | | 釋義 2 | | 公司資料 4 | | 管理層討論及分析 5 | | 其他資料 13 | | 簡明綜合損益及其他全面收益表 23 | | 簡明綜合財務狀況表 24 | | 簡明綜合權益變動表 26 | | 簡明綜合現金流量表 27 | | 簡明綜合財務報表附註 28 | 釋義 | 釋義 | | --- | | 「首次公開發售前購股 | 指 | 本公司於2014年9月25日採納之首次公開發售前購股權計劃 | | --- | --- | --- | | 權計劃」 | | | | 「產品開發分部」 | 指 | 本集團開發以自家品牌出售之自家個人護理產品、保健品及家居產品之業務 分部，該等品牌包括但不限於「衍生」、「太和堂」、「千里馬」、「私+ | | | | 呵護」及「殺菌王」 | | 「人民幣」 | 指 | 中國法定貨幣人民幣 | | 「證券及期貨條例」 | 指 | 證券及期貨條例（香港法例第571章） | | 「股份」 | 指 | 本公司股本中每股面值0.1港元之普通股 | | 「股東」 | 指 | 股份持有人 | | 「購股權計劃」 | 指 | 本公司於2014年9月25 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：6893） 截至2023年9月30日止六個月之 中期業績公佈 財務摘要 截至9月30日 止六個月 20239年月 30日 2022年 變動 千港元 千港元 % 收入 52,318 40,986 27.6% 毛利 32,597 19,519 67.0% ...

目錄 財務摘要 .................................................................................................................................................. 2 釋義 ......................................................................................................................................................... 3 公司資料 .................................................................................................................................................. 5 公司架構 ..................................... ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不會就本公告全部或任何部分 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：6893） 截至2023年3月31日止年度之 全年業績公告 財務摘要 截至3月31日止年度 2023年 2022年 變動 千港元 千港元 % 收入 81,460 120,546 (32.4) 毛利 38,836 69,075 (43.8) ...

衍生集團(國際)控股有限公司 Hin Sang Group (International) Holding Co. Ltd. 股份代號：6893 (於開曼群島註冊成立之有限公司) 2022 / 2023 中期業績報告 isite Packing Milk Supplement (Granule 媽咪少灯 t草經典 科研精髓 20包裝 载 Hin Sang Health Star (Granules) BB好馴啲 父母安心啲 本草經典 科研精髓 匠心品牌 源於 目錄 釋義 2 公司資料 4 管理層討論及分析 5 其他資料 13 簡明綜合損益及其他全面收益表 23 簡明綜合財務狀況表 24 簡明綜合權益變動表 26 簡明綜合現金流量表 27 簡明綜合財務報表附註 28 1 衍生集團（國際）控股有限公司 2022/2023中期業績報告 釋義 於本中期報告中，除文義另有所指外，下列詞彙及詞語具以下的涵義。 | --- | --- | --- | |-------------------------|---------|-------------------------------------------------- ...